ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0810

Spatial Transcriptomic-based Phenotyping of the Fibroblast Niches in Systemic Sclerosis-associated Primary Heart Involvement

Alexandru Micu1, Alexandru-Emil Matei2, Yi-Nan Li3, Ann-Christin Pecher4, Tim Filla5, Jörg Henes6, Markus Eckstein7, Karin Klingel8, Jörg Distler9 and Andrea-Hermina Györfi10, 1Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Germany, 2Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany, Düsseldorf, Germany, 3University Hospital of Düsseldorf, Düsseldorf, Germany, 4Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital Tübingen, Tübingen, Germany, 5Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Germany, 6Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital Tübingen, Tuebingen, Germany, 7Institute of Pathology and Comprehensive Cancer Center EMN, Friedrich-Alexander- Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, 8Cardiopathology, Institute for Pathology, Eberhard-Karls-Universität Tübingen, Tübingen, Germany, 9University Hospital Duesseldorf and HHU, Duesseldorf, Germany, 10Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany

Meeting: ACR Convergence 2025

Keywords: Cell-signalling molecules, Fibroblasts, Other, Heart disease, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: Abstracts: Systemic Sclerosis & Related Disorders – Basic Science (0807–0812)

Session Type: Abstract Session

Session Time: 1:45PM-2:00PM

Background/Purpose: Systemic sclerosis (SSc)-associated primary heart involvement (SSc-pHI) is one of the leading causes of mortality in SSc, yet its underlying cellular and molecular pathomechanisms are poorly understood (1, 2). We aimed to characterize the fibroblast (Fb) subpopulations, their niches and associated cellular networks in SSc-pHI and compare them to those present in other myocardial diseases which associate chronic (postviral myocardial fibrosis (PVMF), hypertrophic cardiomyopathy (HCM), and ischemic cardiomyopathy (ICM)), or acute (acute myocardial infarction (AMI)) fibrotic remodeling using cyclic-in-situ-hybridization.

Methods: We employed the CosMx SMI platform to analyze FFPE myocardial biopsies from 15 SSc-pHI, 10 PVMF, 5 HCM, 5 ICM and 3 AMI patients, examining two 1.8mm2 regions per sample. Gene expression profiling used the Human Universal Cell Characterization RNA Core Panel (950 genes), supplemented with 19 Fb subset markers (3). Data analysis was performed as described previously (4).

Results: We identified 11672 Fb. Spatially informed clustering revealed six Fb populations: GSN/DCN+, AP1+, TIMP1+, COL1A1/POSTN+, NOTCH3+, and myofibroblasts. GSN/DCN+ Fb and myofibroblasts were significantly enriched in SSc-pHI and other forms of chronic compared to acute fibrotic remodeling, while TIMP1+, COL1A1/POSTN+, and NOTCH3+ Fb were significantly upregulated in acute compared to chronic conditions (Figure 1). GSN/DCN+ Fb and AP1+ Fb CNs were enriched and colocalized in the perivascular and the subendocardial areas in chronic conditions, while the NOTCH3+ Fb/COL1A1/POSTN+ Fb CN was enriched in the periinfarct zone in AMI. Furthermore, we observed significant disease-specific changes in the composition of the Fb niches (Figure 2). Functional analyses revealed distinct functions of the Fb populations while spatial interaction analyses showed profound differences in their signaling network in SSc-pHI compared to both other forms of chronic fibrotic remodeling and AMI (Figure 3).

Conclusion: We demonstrate significant alterations in the cellular composition of fibroblasts in SSc-pHI, with altered cellular interactions and signaling in their local niches, compared with other myocardial diseases with acute or chronic fibrotic remodeling. Furthermore, we identified functionally distinct fibroblast populations and uncovered subsets with disease-specific topologies. Our findings provide new insights into the pathophysiology of fibrotic myocardial remodeling and offer potential therapeutic targets.

Supporting image 1Figure 1. Distribution of fibroblast populations across diseases. Statistical significance was assessed using the Kruskal-Wallis test followed by Dunn’s post hoc test with Holm adjustment. * – p-value < 0.05, ** – p-value < 0.01, *** – p-value < 0.001.

Supporting image 2Figure 2. Cellular niche composition and frequencies across diseases.

Supporting image 3Figure 3. Functional analysis of fibroblast populations.


Disclosures: A. Micu: None; A. Matei: None; Y. Li: None; A. Pecher: AstraZeneca, 6, Boehringer-Ingelheim, 1, 6, GlaxoSmithKlein(GSK), 6, UCB, 6; T. Filla: None; J. Henes: AbbVie/Abbott, 1, 6, AstraZeneca, 1, 6, Boehringer-Ingelheim, 1, 6, Bristol-Myers Squibb(BMS), 1, 6, Eli Lilly, 1, Janssen, 1, 6, Novartis, 1, 1, 6, 6, Otsuka, 1, Pfizer, 1, Roche, 1, SOBI, 1, UCB, 1, 6; M. Eckstein: None; K. Klingel: None; J. Distler: 4D Science, 8, 11, Actelion, 2, 6, Active Biotech, 2, 6, Anamar, 2, 6, Array Biopharma, 2, 6, ARXX Therapeutics, 2, 6, aTyr Pharma, 2, 6, Bayer Pharma, 2, 6, BMS (Bristol-Myers Squibb), 2, 6, Boehringer Ingelheim, 2, 6, Celgene, 2, 6, FibroCure, 4, Galapagos, 2, 6, GSK, 2, 6, Inventiva, 2, 6, JB Therapeutics, 2, 6, Medac, 2, 6, Novartis, 2, 6, Pfizer, 2, 6, Redx Pharma, 2, 6, RuiYi, 2, 6, Sanofi-Aventis, 2, 6, UCB, 2, 6; A. Györfi: AbbVie, 6, Boehringer-Ingelheim, 6.

To cite this abstract in AMA style:

Micu A, Matei A, Li Y, Pecher A, Filla T, Henes J, Eckstein M, Klingel K, Distler J, Györfi A. Spatial Transcriptomic-based Phenotyping of the Fibroblast Niches in Systemic Sclerosis-associated Primary Heart Involvement [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/spatial-transcriptomic-based-phenotyping-of-the-fibroblast-niches-in-systemic-sclerosis-associated-primary-heart-involvement/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/spatial-transcriptomic-based-phenotyping-of-the-fibroblast-niches-in-systemic-sclerosis-associated-primary-heart-involvement/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology